MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Vladonix Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Vladonix is the oral thymus peptide bioregulator (the A-6 Cytomax) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Each capsule supplies about 10 mg of a low-molecular-weight peptide complex isolated from calf thymus. The proposed mechanism is tissue-specific gene regulation: short peptides are thought to penetrate immune-cell nuclei and bind gene-promoter sites, upregulating proteins that mature T-lymphocytes and normalize the CD4/CD8 ratio (PMID 23484211; PMC8999041). A manufacturer clinical report in 42 post-radiation and oncology patients described normalization of immune indices in about 78% of cases with no recorded side effects, and the related injectable Thymalin doubled lymphocyte subsets and halved mortality in severe COVID-19 (PMC8654498). Typical use is 10-20 mg/day with meals over a 20-30 day course, repeated 2-3 times yearly. Vladonix is not FDA- or EMA-approved; it is sold as a supplement or research bioregulator, and the subcutaneous figures here are an educational measurement reference only.
Reconstitute: Add 1 mL bacteriostatic water → 20 mg/mL concentration.
Typical dose: 10-20 mg/day orally (1-2 × 10 mg capsules)
Easy measuring: At 20 mg/mL, 1 unit = 0.01 mL = 0.2 mg (200 mcg) on a U-100 insulin syringe.
Storage: Sealed capsules stored below 25 °C, protected from light; shelf life about 3 years. The educational reconstituted solution should be refrigerated at 2-8 °C, protected from light, and used within ~4 weeks.
Half-life: Not formally established; short peptides clear from plasma within minutes, while the bioregulatory effect is assumed to persist over a 20-30 day course (no published Cmax/Tmax/bioavailability).
Route: Oral capsules, 1-2 × 10 mg with meals; the subcutaneous reconstitution scheme here is an educational measurement reference only (the injectable thymic analogue is Thymalin).
Status: Not FDA- or EMA-approved; sold as a dietary supplement / research bioregulator. Evidence is mainly non-replicated single-center studies. Educational content, not medical advice.
About Vladonix
Vladonix is a Khavinson thymus peptide bioregulator — the oral A-6 "Cytomax" — a complex of low-molecular-weight peptides (under ~10,000 Da) isolated from the thymus of calves under 12 months and produced at the St. Petersburg Institute of Bioregulation and Gerontology [1][3]. It is marketed as an immune-support supplement meant to help restore T-cell immunity after infection, stress, radiation, or chemotherapy [1].\n\nThe established Vladonix dosage is oral: 1-2 capsules of 10 mg each, once or twice daily with meals, for a 20-30 day course that is typically repeated two to three times per year. More intensive clinical regimens used up to 1-3 capsules two-to-three times daily for 15-20 days in patients with marked immunodeficiency [1]. Clinically this product is swallowed, not injected — the subcutaneous vial-and-bacteriostatic-water figures below are the site's standard educational measurement reference, not the real route (the injectable thymic peptide in the Khavinson system is Thymalin, not Vladonix) [3].\n\nThis guide models a 20 mg vial reconstituted with 1.0 mL of bacteriostatic water (20 mg/mL, 200 mcg per insulin-syringe unit) so the oral milligram doses map cleanly onto a U-100 syringe: 10 mg ≈ 50 units, 20 mg ≈ 100 units, and a 30 mg intensive dose ≈ 150 units (split across two injections).\n\nFrequency: Once daily with meals across a 20-30 day course, repeated 2-3 times yearly. Vladonix is not FDA- or EMA-approved and is presented here for educational purposes only, not as medical advice.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 1.0 mL of bacteriostatic water into a sterile syringe.
Inject the water slowly down the inner wall of the 20 mg Vladonix vial; do not aim the stream directly at the powder, and avoid vigorous shaking.
Gently swirl or roll the vial until the solution is completely dissolved and clear; the result is a 20 mg/mL concentration (200 mcg per U-100 insulin-syringe unit).
Store refrigerated at 2-8 °C and draw the prescribed units per dose: 10 mg ≈ 50 units, 20 mg ≈ 100 units (a full syringe), and a 30 mg intensive dose ≈ 150 units split across two injections.
Educational note: Vladonix is clinically taken ORALLY as 10 mg capsules with meals; these subcutaneous reconstitution figures are a measurement reference only and are not a recommendation to inject this oral product.
Interactive Vladonix Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 1 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 1mL water yields 20.00 mg/mL. To evaluate a 250mcg dose, pull to 1.3 units (1 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Starter / light immune support — ~1 capsule equivalent | 10000 mcg (10 mg) | 50 units (0.50 mL) |
| Standard 20-30 day course — 2 × 10 mg/day | 20000 mcg (20 mg) | 100 units (1.00 mL) |
| Intensive clinical range (marked immunodeficiency, split dose) | 30000 mcg (30 mg) | 150 units (1.50 mL) |
Administration guidelines: Refer to guidelines | 1 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Vladonix, 20 mg each):
- checkStandard 20-30 day course at 20 mg/day ≈ 20-30 vials (400-600 mg total) — the realistic way this product is used
- check8-week continuous model at 20 mg/day ≈ 56 vials (1,120 mg)
- check12 weeks ≈ 84 vials; 16 weeks ≈ 112 vials — the high counts illustrate why Vladonix is taken orally as inexpensive 10 mg capsules, not injected
Insulin Syringes (U-100):
- checkOnce-daily dosing: 7 syringes per week
- check8 weeks ≈ 56 syringes; 12 weeks ≈ 84 syringes; 16 weeks ≈ 112 syringes
- checkIntensive 30 mg doses (≈150 units) exceed one 1 mL syringe and need a split (2 × ~75 units), roughly doubling syringe use
Bacteriostatic Water (30 mL bottles): Use 1 mL per 20 mg vial for reconstitution.
- check20-30 day course ≈ 20-30 mL ≈ 1 bottle
- check8 weeks ≈ 56 mL ≈ 2 bottles; 12 weeks ≈ 84 mL ≈ 3 bottles
- check16 weeks ≈ 112 mL ≈ 4 bottles
Alcohol Swabs:
- check1-2 swabs per dose (vial top + injection site)
- check8 weeks ≈ 60-120 swabs; 12 weeks ≈ 90-170 swabs
- check16 weeks ≈ 120-230 swabs; keep extras for re-swabbing multi-use vials
Mechanism of Action (MOA)
Vladonix is a "Cytomax" — a naturally derived peptide bioregulator rather than a single synthetic molecule. It is a complex of low-molecular-weight peptides (generally under ~10,000 Da) extracted from the thymus of calves under 12 months of age, the same tissue source used for the injectable thymic preparation Thymalin [3]. The Khavinson bioregulator hypothesis holds that the short peptides released from this complex are tissue-specific signaling molecules: small enough to cross the cell and nuclear membranes, they are proposed to bind directly to specific gene-promoter sequences in thymic and immune-cell DNA and thereby modulate transcription of immune proteins [5][6]. Molecular-modeling studies describe di-, tri- and tetrapeptide motifs (such as the Lys-Glu and Glu-Trp fragments characteristic of thymic peptides) interacting electrostatically with double-stranded DNA at promoter sites [5].\n\nFunctionally, the downstream effect attributed to thymic peptide bioregulators is restoration of T-cell immunity: accelerated maturation and differentiation of T-lymphocytes, normalization of the CD4+/CD8+ ratio, rebalancing of T- and B-cell populations, and modulation of cytokine output [1][3]. In cultured monocyte/macrophage (THP-1) cells, thymus-derived peptides increased mitogen-activated kinase phosphorylation and STAT1 signaling while suppressing LPS-induced TNF and IL-6, consistent with an immune-normalizing rather than purely stimulatory action [4]. The framework is described as epigenetic: the peptides are thought to act as gene-expression modulators that nudge an imbalanced immune system back toward homeostasis [6][8].\n\nPharmacokinetics: Vladonix is taken orally as capsules, so the active peptides are released in the gastrointestinal tract. No formal human pharmacokinetic profile (Cmax, Tmax, bioavailability) has been published, and a meaningful plasma half-life has not been characterized — short peptides of this type are hydrolyzed by plasma and tissue peptidases within minutes, so any biological effect is presumed to outlast measurable plasma concentrations. This is why the compound is dosed as a multi-week course (typically 20-30 days) repeated two to three times per year rather than titrated to a steady plasma level [1].\n\nRoute reality: clinically and commercially, Vladonix is an oral capsule (1-2 × 10 mg with meals). The subcutaneous vial-and-bacteriostatic-water reconstitution scheme presented on this page is the site's standard educational measurement convention, not a validated delivery method for this product; the injectable counterpart in the Khavinson system is Thymalin, not Vladonix [3]. Vladonix is not approved as a drug by the FDA or EMA; it is sold as a dietary supplement / research bioregulator, and the evidence base is dominated by Russian-language studies from a single research center that have not been independently replicated in Western randomized trials [2][7].
Clinical Trial Efficacy Highlights
- starIn the manufacturer's clinical report from the Medical Center of the St. Petersburg Institute of Bioregulation and Gerontology, 42 patients (23 men, 19 women, ages 34-65) with secondary immunodeficiency after low-dose ionizing radiation or oncological radiation/chemotherapy received Vladonix (1-3 capsules, 2-3 times daily for 15-20 days); immune parameters normalized in roughly 78% of cases, with significant increases in CD3+ and CD4+ lymphocytes and improvement of the CD4+/CD8+ ratio (p<0.05) versus controls, and 100% of oncology patients completed therapy versus 79% of controls [1].
- starKhavinson and Morozov's 6-8 year controlled observation in 266 elderly people reported that annual courses of the injectable thymic bioregulator Thymalin reduced mortality roughly 2.0-2.1-fold, and Thymalin combined with the pineal peptide Epithalamin reduced it about 4.1-fold versus controls, alongside fewer acute respiratory infections — the foundational longevity data for the thymic-peptide class, though from a single center [2].
- starIn a controlled study of severe COVID-19 in older patients (Kuznik, Khavinson et al., 2021), injectable Thymalin (10 mg intramuscularly daily for 10 days) roughly doubled circulating T-, B- and NK-cell and CD4+/CD8+ counts, lowered IL-6 about 6.5-fold, and halved hospital mortality (19.4% vs 40.9%) — direct evidence that a thymic-peptide preparation can re-regulate a dysregulated immune response, noting Vladonix is the oral Cytomax analogue rather than the injectable [3].
- starAvolio, Martinotti, Khavinson and colleagues (Int J Mol Sci, 2022) showed in the human monocyte/macrophage THP-1 line that thymus-derived peptides (Thymalin and the dipeptide Thymogen) modulated proliferative signaling (increased MAPK tyrosine phosphorylation and STAT1) and suppressed LPS-induced TNF and IL-6 plus monocyte-endothelial adhesion, providing an in-vitro mechanism for the immune-normalizing action attributed to this class [4].
- starKhavinson, Tarnovskaya and colleagues (Bull Exp Biol Med, 2013) used molecular modeling to show how short cell-penetrating peptides can interact with specific gene-promoter sites, supporting the proposed nucleus-level, gene-regulatory mechanism that underpins the entire bioregulator concept [5].
- starA peer-reviewed review by Janssens et al. (Clinical Epigenetics, 2019) places Khavinson short peptides within the broader, independently described category of peptides acting as epigenetic modulators of gene expression, lending external context to the mechanism even though it does not validate the specific Vladonix product [6].
- starKhavinson's monograph 'Peptides and Ageing' (2002) and a later systematic review of peptide regulation of gene expression (2021) summarize four decades of bioregulator research; importantly, the strongest Vladonix-specific evidence remains the manufacturer's small, non-randomized, unblinded report, so claimed benefits should be read as preliminary rather than as proven clinical efficacy [7][8].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningThe manufacturer's clinical report documented no side effects, complications, contraindications, or drug dependence at the doses studied, and oral thymic-peptide bioregulators are generally described as well tolerated [1] — but this reflects small, unblinded studies, not large controlled safety trials.
- warningListed contraindications are pregnancy, breastfeeding, age under 14, and individual intolerance to any component; these groups should not use the product.
- warningBecause the peptides are extracted from bovine (calf) thymus tissue, there is a theoretical risk of allergic or immunogenic reaction and the general (very low but non-zero) concern attached to any animal-tissue-derived product; sourcing and quality control vary by vendor.
- warningAs an immunomodulator it should be used cautiously, and only with medical guidance, by people with autoimmune disease, lymphoproliferative disorders, or organ transplants, where shifting T-cell balance could be undesirable.
- warningIt is not a substitute for vaccination, antibiotics, antivirals, or oncologic therapy; using it in place of evidence-based treatment for a serious infection or cancer is dangerous.
- warningRoute caveat: Vladonix is an oral capsule. The subcutaneous reconstitution protocol shown here is an educational measurement model only and has not been tested for safety or sterility as an injection — do not treat these figures as an endorsement to inject this product.
- warningRegulatory/research status: Vladonix is NOT approved as a drug by the FDA or EMA. In the US it is sold as a dietary supplement or research material; the evidence base is dominated by non-replicated single-center studies, so it should be regarded as experimental and educational, not a proven therapy [2][7].
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Vladonix dosage?expand_more
The typical Vladonix dosage is 10-20 mg per day, taken as one or two 10 mg capsules with meals, for a 20-30 day course that is usually repeated two to three times per year. Each capsule supplies about 10 mg of thymus peptide complex. In the clinical report, more intensive regimens of up to 1-3 capsules two to three times daily (roughly 20-60 mg/day) were used for 15-20 days in patients with marked immunodeficiency. It is dosed orally; the subcutaneous milligram/unit figures on this page are an educational measurement reference only.
Is Vladonix FDA approved?expand_more
No. Vladonix is not approved by the FDA or the EMA as a drug for any indication. It originates from the St. Petersburg Institute of Bioregulation and Gerontology and is registered or sold in some countries as a dietary supplement (parapharmaceutical) and elsewhere as a research bioregulator. Its evidence base comes largely from Russian single-center studies that have not been independently replicated in Western randomized controlled trials, so it should be treated as an educational/research compound, not an approved medicine.
What is the half-life of Vladonix?expand_more
There is no formally established half-life for Vladonix. It is an orally administered complex of short peptides, and peptides of this class are broken down by plasma and tissue peptidases within minutes, so a meaningful steady-state plasma half-life has not been characterized. The bioregulator model assumes the gene-regulatory effect outlasts the peptides' brief presence in the blood, which is why it is given as a multi-week course rather than dosed to a target blood level. No human pharmacokinetic profile (Cmax, Tmax, bioavailability) has been published.
How is Vladonix reconstituted and dosed for the educational model?expand_more
In real-world use Vladonix needs no reconstitution — it is swallowed as a capsule. For the site's educational subcutaneous model, a 20 mg vial is mixed with 1.0 mL of bacteriostatic water to give 20 mg/mL (200 mcg per insulin-syringe unit): 10 mg ≈ 50 units, 20 mg ≈ 100 units (a full U-100 syringe), and a 30 mg intensive dose ≈ 150 units would be split across two injections. Draw the water slowly down the vial wall, swirl gently until clear, and refrigerate. Again, this is a measurement reference, not a recommendation to inject the oral product.
Can Vladonix be stacked with other Khavinson peptide bioregulators?expand_more
In the bioregulator tradition, organ-specific Cytomaxes are often run together or sequentially — for example pairing the thymic Vladonix with a pineal peptide such as Endoluten, mirroring the original longevity studies that combined Thymalin with Epithalamin. There is, however, no controlled safety data for any specific stack, and combining immune-active and other tissue-targeted peptides is experimental. Anyone considering a stack — especially alongside prescription drugs, immunosuppressants, or during cancer therapy — should consult a physician first.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Vladonix, plus the universal dosing calculator.
Academic References & Study Citations
Khavinson VKh. REPORT on the results of the clinical study of the biologically active peptide bioregulator Vladonix. Medical Center, St. Petersburg Institute of Bioregulation and Gerontology, 2003-2004 (42-patient post-radiation/oncology immune study). View Scientific Paper →
Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363. View Scientific Paper →
Kuznik BI, Khavinson VKh, Shapovalov KG, et al. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients. Adv Gerontol. 2021;11(4):368-376. doi:10.1134/S2079057021040068. View Scientific Paper →
Avolio F, Martinotti S, Khavinson VKh, et al. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. Int J Mol Sci. 2022;23(7):3607. doi:10.3390/ijms23073607. PMID: 35408963. View Scientific Paper →
Khavinson VKh, Tarnovskaya SI, Linkova NS, et al. Short cell-penetrating peptides: a model of interactions with gene promoter sites. Bull Exp Biol Med. 2013;154(3):403-410. PMID: 23484211. View Scientific Paper →
Janssens Y, Wynendaele E, Vanden Berghe W, De Spiegeleer B. Peptides as epigenetic modulators: therapeutic implications. Clin Epigenetics. 2019;11:101. doi:10.1186/s13148-019-0700-7. View Scientific Paper →
Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23(Suppl 3):11-144. PMID: 12374906. View Scientific Paper →
Khavinson VKh, Linkova NS, Kvetnoy IM, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. doi:10.3390/molecules26227053. View Scientific Paper →